Racial Differences in Vagal Control of Glucose Homeostasis

Study Overview
=================
Brief Summary
-----------------
The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.

Detailed Description
-----------------
Obesity has a greater detrimental impact on the health of African American women (AAW) than on any other racial or gender group. Nearly 80% of AAW are overweight or obese. Reduced insulin sensitivity is more prevalent among AAW as compared to white women and men of both races. This condition puts AAW at increased risk for the development of type 2 diabetes mellitus. The exact mechanism underlying these pathophysiological differences remains unknown. The investigators have found that obese AAW have decreased parasympathetic nerve (PNS) activity compared to whites and recent studies in animal models showed that the PNS confers protection against oxidative stress. In our AA cohort, PNS activity was directly correlated with insulin sensitivity in obese AAW even after controlling for differences in age, blood pressure and visceral adiposity. Equally important, the investigators also showed that the decrease in insulin sensitivity was associated with increased oxidative stress as measured by plasma levels of F2-isoprostanes. Taken together these findings lead us to hypothesize that the decreased PNS activity in obese AAW compared to white women has deleterious effects on oxidative stress and insulin sensitivity.The investigators will test the hypothesis that acute central acetylcholinesterase inhibition will restore PNS activity and reduce oxidation in AAW compared to whites.

Official Title
-----------------
Racial Differences in Vagal Control of Glucose Homeostasis

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Drug: Galantamine
* Drug: Placebo Oral Capsule
* Drug: Intralipid
* Drug: Heparin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female African American or white (race will be self-defined, but only subjects who report both parents of the same race will be included) 18-60 years old BMI 30-45 Kg/m2 Not pregnant or breastfeeding Exclusion Criteria: Pregnant or breastfeeding Diabetes diagnosis (defined by the American Diabetes Association (ADA) criteria)38 Cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy. Arrhythmia (first-, second-, and third-degree atrioventricular (AV) block) Significant weight change >5% in the past 3 months Impaired hepatic function (AST and/or Alanine transaminase (ALT) > one and one half times (1.5X) upper limit of normal range) Impaired renal function (eGFR <60ml/min) Users of strong inhibitors of Cytochrome P450 3A4 (CYP3A4) or cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) Users of other acetylcholinesterase inhibitors such as pyridostigmine or bethanechol History of alcohol or drug abuse Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Galantamine 16 mg then placebo<br>Galantamine 16 mg po one time dose then placebo on 2nd visit | Drug: Galantamine<br>* 16 mg po prior to the infusion of intralipid<br>* Other names: Razadyne;Drug: Placebo Oral Capsule<br>* Placebo oral capsule prior to the infusion of intralipid/heparin<br>Drug: Intralipid<br>* Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine<br>* Other names: I.V. Fat Emulsion;Drug: Heparin<br>* heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine<br>|
| Placebo Comparator: Placebo then Galantamine 16 mg<br>Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit | Drug: Galantamine<br>* 16 mg po prior to the infusion of intralipid<br>* Other names: Razadyne;Drug: Placebo Oral Capsule<br>* Placebo oral capsule prior to the infusion of intralipid/heparin<br>Drug: Intralipid<br>* Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine<br>* Other names: I.V. Fat Emulsion;Drug: Heparin<br>* heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Oxidative Stress: Baseline to 2 Hours | Measure F-2 isoprostanes as a marker of oxidation | Baseline to 2 hours | 
| Change in Oxidative Stress: Baseline to 4 Hours | Measure F-2 isoprostanes as a marker of oxidation | Baseline to 4 hours |